New York State Common Retirement Fund Acquires 4,136 Shares of Cencora, Inc. (NYSE:COR)

New York State Common Retirement Fund lifted its position in Cencora, Inc. (NYSE:COR - Free Report) by 3.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 116,494 shares of the company's stock after purchasing an additional 4,136 shares during the quarter. New York State Common Retirement Fund owned 0.06% of Cencora worth $32,396,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in COR. Net Worth Advisory Group lifted its position in Cencora by 1.4% during the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock worth $736,000 after buying an additional 36 shares in the last quarter. Cromwell Holdings LLC increased its stake in shares of Cencora by 9.5% in the 1st quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock valued at $125,000 after acquiring an additional 39 shares during the last quarter. Whittier Trust Co. increased its stake in shares of Cencora by 0.6% in the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after acquiring an additional 44 shares during the last quarter. Private Trust Co. NA increased its stake in shares of Cencora by 2.5% in the 1st quarter. Private Trust Co. NA now owns 1,933 shares of the company's stock valued at $538,000 after acquiring an additional 47 shares during the last quarter. Finally, Permanent Capital Management LP increased its stake in shares of Cencora by 4.0% in the 1st quarter. Permanent Capital Management LP now owns 1,238 shares of the company's stock valued at $344,000 after acquiring an additional 48 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Trading Down 0.1%

COR stock traded down $0.29 during midday trading on Friday, hitting $294.09. 448,885 shares of the company's stock were exchanged, compared to its average volume of 1,501,709. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The business has a 50-day simple moving average of $292.19 and a two-hundred day simple moving average of $271.61. The stock has a market capitalization of $57.00 billion, a PE ratio of 34.14, a P/E/G ratio of 1.48 and a beta of 0.57. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The company had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the previous year, the firm posted $3.80 EPS. The firm's quarterly revenue was up 10.3% on a year-over-year basis. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. Cencora's payout ratio is 25.52%.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the sale, the chairman owned 311,913 shares of the company's stock, valued at $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,127 shares of company stock worth $9,812,296 over the last quarter. 10.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on COR. Bank of America increased their price objective on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. UBS Group lifted their target price on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Morgan Stanley set a $330.00 price target on Cencora and gave the stock an "equal weight" rating in a research report on Wednesday. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Finally, Robert W. Baird lifted their price objective on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and an average target price of $309.83.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.